These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8743044)

  • 1. Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Whelton PK; Williamson JD; Louis GT; Davis BR; Cutler JA
    Clin Exp Hypertens; 1996; 18(3-4):569-79. PubMed ID: 8743044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
    Furberg CD; Psaty BM; Pahor M; Alderman MH
    Ann Intern Med; 2001 Dec; 135(12):1074-8. PubMed ID: 11747386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Player MS; Gill JM; Fagan HB; Mainous AG
    J Clin Hypertens (Greenwich); 2006 Dec; 8(12):860-4. PubMed ID: 17170611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
    Xie F; Petitti DB; Chen W
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):464-9. PubMed ID: 15831354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
    Scheen AJ; Krzesinski JM
    Rev Med Liege; 2003 Jan; 58(1):47-52. PubMed ID: 12647599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors].
    Scholze J; Unger T
    Internist (Berl); 2003 Sep; 44(9):1193-5. PubMed ID: 14566471
    [No Abstract]   [Full Text] [Related]  

  • 11. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Pressel S; Davis BR; Louis GT; Whelton P; Adrogue H; Egan D; Farber M; Payne G; Probstfield J; Ward H;
    Control Clin Trials; 2001 Dec; 22(6):674-86. PubMed ID: 11738123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Pressel SL; Davis BR; Wright JT; Geraci TS; Kingry C; Ford CE; Piller LB; Bettencourt J; Kimmel B; Lusk C; Parks H; Simpson LM; Nwachuku C; Furberg CD;
    Control Clin Trials; 2001 Feb; 22(1):29-41. PubMed ID: 11165421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS;
    Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
    Düsing R
    Dtsch Med Wochenschr; 2003 Jan; 128(5):214-6. PubMed ID: 12557115
    [No Abstract]   [Full Text] [Related]  

  • 19. The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Kronish IM; Lynch AI; Oparil S; Whittle J; Davis BR; Simpson LM; Krousel-Wood M; Cushman WC; Chang TI; Muntner P
    Hypertension; 2016 Jul; 68(1):39-45. PubMed ID: 27217410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.
    Oparil S
    Hypertension; 2003 May; 41(5):1006-9. PubMed ID: 12695423
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.